An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Autor: Takeuchi E; Department of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi, Japan., Ogino H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan., Kondo K; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan., Okano Y; Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan., Ichihara S; Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan., Kunishige M; Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan., Kadota N; Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan., Machida H; Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan., Hatakeyama N; Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan., Naruse K; Department of Pathology, National Hospital Organization Kochi Hospital, Kochi, Japan., Nokihara H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan., Shinohara T; Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan., Nishioka Y; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Jazyk: angličtina
Zdroj: Thoracic cancer [Thorac Cancer] 2024 Jan; Vol. 15 (3), pp. 248-257. Date of Electronic Publication: 2023 Dec 12.
DOI: 10.1111/1759-7714.15191
Abstrakt: Background: An increased relative eosinophil count (REC) has potential as a predictive biomarker for a beneficial clinical response and outcome to cancer immunotherapies. Therefore, the present study investigated the impact of an increased posttreatment REC on the prognosis of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
Methods: We retrospectively reviewed all 151 patients diagnosed with NSCLC and treated with ICI monotherapy and blood test data between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
Results: A total of 151 patients with a mean age of 69 years were included. REC after 4 weeks of initial ICI monotherapy was higher than pretreatment REC in 87 patients but not in 64. REC after 4 weeks of the ICI treatment with and without an increased REC were 4.4 and 1.8%, respectively (p < 0.001). Disease control rates (DCR) were significantly higher in patients with than in those without an increased REC (84% vs. 47%, p < 0.001). The median overall survival (OS) of lung cancer patients with or without an increased REC were 674 and 234 days, respectively. A Kaplan-Meier univariate analysis revealed a significant difference in OS between the two groups (p < 0.001). A Cox proportional regression analysis identified an increased REC as an independent predictor of OS (p = 0.003).
Conclusion: ICI-treated NSCLC patients with an increased REC after 4 weeks of treatment had a better DCR and prognosis than the other patients examined.
(© 2023 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje